CONCENTRATION OF FREE METALLOPROTEINASE MMP9 AND COMPLEX MMP9/TIMP1 IN BLOOD SERUM IN PATIENTS WITH CO-EXISTING STABLE CHRONIC OBSTRUCTIVE LUNG DISEASE AND ISCHEMIC HEART DISEASE

Summary. We analyzed concentration of matrix metalloproteinase MMP9 and complex MMP9/TIMP1 in blood serum in patients with chronic obstructive pulmonary disease (COPD) and in patients with co-existing COPD and ischemic heart disease (IHD).

Serum concentration of complex MMP9/TIMP1 in patients with COPD was significantly higher than in controls. Patients with COPD stage III had higher concentration of the complex than those with COPD stage II. It is important that MMP9/TIMP1 concentration increased more significantly in patients with combined pathology than in patients with COPD. Difference between MMP9 level in patients with COPD and in patients with co-existing COPD and IHD was estimated. Highest levels of MMP9 were found in patients with combined disease.

Therefore, concentrations of MMP9 and MMP9/TIMP1 positively correlated with COPD severity both in patients with COPD and with combination of COPD and IHD.

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management,and prevention of chronic obstructive pulmonary disease.NHLBI / WHO workshop report. Last update 2008.

2. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640–2646.

3. Curkendall S.M., Lanes S., de Luise C. et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006; 21 (11): 803–813.

4. Oikonomidi S., Kostikas K., Tsilioni I. et al. Matrix metallo-proteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr. Med. Chem. 2009; 16(10): 1214–1228.

5. Atkinson J.J., Senior R.M. Matrix metalloproteinase-9 in lung remodeling. Am. J. Respir. Cell Mol. Biol. 2003; 28:12–24.

6. Zouridakis E., Avanzas P., Arroyo-Espliguero R. et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110 (13): 1747–1753.

7. Agusto A.G.N., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J.2003; 21: 347–360.

8. Morris A., Kinnear G., Wan W. Y. et al. Comparison of cigarette smoke induced acute inflammation in multiple strains of mice and the effect of a matrix metalloproteinase inhibitor on these responses. J. Pharmacol. Exp. Ther. 2008;327 (3): 851–862.

9. Mercer P.F. The role of matrix metalloproteinase-9 in the pathogenesis of chronic obstructive pulmonary disease.Dissertat. Abstr. Int.: Proquest 2003; 63 (3): 437.

10. Agusto A.G.N., Noguera A., Sauleda J. et al. Systemic inflammation in chronic respiratory disease. J. Nutr. Metab. Chron. Respir. Dis. 2003; 24: 46–55.

11. Churg A., Wang R.D., Tai H. et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-release. Am. J. Respir. Crit. Care Med. 2003; 167: 1083–1089.

12. Kim S.E., Thanh Thuy T.T., Lee J.H. et al. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp.Mol. Med. 2009; 41 (4): 277–287.

13. Pons A.R., Sauleda J., Noguera A. et al. Decreased macrophage release of TGF beta and TIMP-1 in chronic obstructive pulmonary disease. Eur. Respir. J. 2005; 26: 60–66.

14. Brajer B., Kuznar-Kaminska B., Nowicka A. et al. Increased concentration of matrix metalloproteinase-9 in serum of COPD patients. Eur. Respir. J. 2005; 26 (49): 54.

15. Barkhatova D.A., Nevzorova V.A., Shekunova O.I., Brod-skaya T.A. Сytokines, extracellular matrix metalloproteinases and arterial stiffness in COPD. 18-th European respiratory society annual congress: Abstracts. Berlin; 2008.589.